Venetoclax plus rituximab or obinutuzumab after allogeneic hematopoietic stem cell transplantation in chronic lymphocytic leukemia

類似資料

• Venetoclax and obinutuzumab in chronic lymphocytic leukemia
  著者:: Fischer, Kirsten, 等
  出版事項: (2017)
• What is known about palliative care in adult patients with allogeneic stem cell transplantation (allo-SCT)?
  著者:: Simon, Steffen T., 等
  出版事項: (2021)
• Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia
  著者:: Fischer, Kirsten, 等
  出版事項: (2020)
• Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy
  著者:: Al-Sawaf, Othman, 等
  出版事項: (2017)
• Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia (Comment to Tausch et al.)
  著者:: Weiss, Jonathan, 等
  出版事項: (2019)